In situ delivery of synthetic preimplantation factor using aldehyde-modified hyaluronic acid hydrogel with immobilized complexes of chondroitin sulfate derivatives

In situ delivery of synthetic preimplantation factor using aldehyde-modified hyaluronic acid hydrogel with immobilized complexes of chondroitin sulfate derivatives

Synthetic preimplantation factor (SPIF) is a promising therapeutic agent for chronic inflammatory diseases like Multiple Sclerosis (MS), but frequent systemic dosing limits patient adherence and therapy efficacy. This study presents an injectable drug delivery system (DDS) using 2 % (w/v) aldehyde-m...

Full description

Saved in:
Bibliographic Details
Main Authors: Tutut Habibah, Andrea Exnerová, Kristina Nešporová, Una FitzGerald, Abhay Pandit, Marek Ingr, Martin Pravda, Vladimír Velebný
Format: Article
Language:English
Published: Elsevier 2025-03-01
Series:Carbohydrate Polymer Technologies and Applications
Subjects:
Hydrogel
Synthetic preimplantation factor
Hyaluronic acid, Chondroitin sulfate
Polyelectrolyte complexes
Online Access:http://www.sciencedirect.com/science/article/pii/S2666893925000283
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Synthetic preimplantation factor (SPIF) is a promising therapeutic agent for chronic inflammatory diseases like Multiple Sclerosis (MS), but frequent systemic dosing limits patient adherence and therapy efficacy. This study presents an injectable drug delivery system (DDS) using 2 % (w/v) aldehyde-modified hyaluronic acid (HAOX) and chondroitin sulfate (CSOX) to deliver 100 µg of Fluorescein isothiocyanate-modified SPIF (FITC-SPIF). The DDS utilizes electrostatic interactions between the negatively charged sulfate groups of CSOX and the positively charged amino acids of FITC-SPIF for effective entrapment. Key properties were analyzed, including moderate gelation time (193 s), swelling profile (18 %), injectability (27 G needle) and an established relevant release profile (20 μg/daily ± 3) via anomalous diffusion. Increasing CSOX concentration reduced initial burst release by 38 % (0.5 % CSOX) to 78 % (1 % CSOX), extending release time (T50 %) from 50 h (0.5 % CSOX) to 88 h (1 % CSOX). Additionally, the release of FITC-SPIF enhanced TGF-β secretion in THP-1 macrophages, indicating preserved biological activity. These findings highlight the tunable release and mechanical properties achieved by adjusting the HAOX:CSOX ratio, strategically aligning the DDS for targeted MS symptom management. This system potentially simplifies SPIF delivery and enhances therapeutic efficacy.
ISSN:2666-8939

Similar Items